Three decades of advances in diabetes care have transformed how people with type 1 diabetes manage glucose. Insulin pumps, continuous glucose monitoring (CGM), improved insulin analogs, automated insulin delivery, and earlier screening have all changed daily treatment. However, have these advances actually reduced the long-term complications of type 1 diabetes? …
Read More »The Return of Aldose Reductase Inhibitors: Could an Old Idea Finally Pay Off?
Diabetes care has advanced dramatically over the past decade. While therapies such as GLP-1 receptor agonists and SGLT2 inhibitors have transformed glucose management and cardiovascular outcomes, many patients continue to develop long-term complications. Could an older therapeutic target finally provide the missing piece? Interest in aldose reductase inhibitors for diabetes …
Read More »GLP-1s and Microvascular Complications: Do They Change Neuropathy Trajectory?
Cardiovascular outcomes often dominate discussions about GLP-1 receptor agonists, but what about nerve health? Growing interest in GLP-1 diabetic neuropathy reflects a broader shift toward understanding microvascular complications beyond heart disease. While medications such as semaglutide (Ozempic), dulaglutide (Trulicity), and liraglutide (Victoza) have proven cardiovascular benefits, their potential influence on …
Read More »Microvascular Complications in Diabetes: Screening and Management
Diabetes is a chronic condition affecting millions of people worldwide. One of the most serious complications of diabetes is microvascular disease, which can cause damage to the small blood vessels in the body and lead to a range of serious health problems. To help prevent and manage microvascular complications, it …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.